Metastatic Castration-Resistant Prostate Cancer with BRCA2 Mutation: The Challenge Incorporating PARP Inhibitors and Platinum in Treatment Sequencing
  • Inês Costa
    Medical Oncology Department, Centro Hospitalar e Universitário de São João, Porto, Portugal https://orcid.org/0000-0002-0383-8584
  • Joana Reis
    Medical Oncology Department, Centro Hospitalar e Universitário de São João, Porto, Portugal
  • Sara Meireles
    Medical Oncology Department, Centro Hospitalar e Universitário de São João, Porto, Portugal
  • Maria João Ribeiro
    Medical Oncology Department, Centro Hospitalar e Universitário de São João, Porto, Portugal
  • Isabel Augusto
    Medical Oncology Department, Centro Hospitalar e Universitário de São João, Porto, Portugal
  • Miguel Barbosa
    Medical Oncology Department, Centro Hospitalar e Universitário de São João, Porto, Portugal

Keywords

Metastatic prostate cancer, BRCA2 germline mutation, PARP inhibitor, olaparib, carboplatin, BRCA2-mutated metastatic castration-resistant prostate cancer

Abstract

Prostate cancer is the second most frequent malignancy in men worldwide. Despite the improvement in survival achieved by increasingly early diagnosis and advances in treatment, it is still associated with high mortality. Because of its molecular heterogeneity, there is a need to identify genetic alterations in order to apply targeted therapies. Increasing evidence suggests that the PARP inhibitor olaparib could have a significant synthetic lethal effect in prostate cancer with homologous recombination defects, such as BRCA1/2 mutations. It is not yet known if, under these circumstances, platinum-based chemotherapy induces higher response rates in prostate cancer. We present the case of a patient with BRCA2-mutated metastatic castration-resistant prostate cancer whose treatment sequence included carboplatin and olaparib.

VIEW THE ENTIRE ARTICLE

References

  • World Health Organization. International Agency for Research on Cancer. Global Cancer Observatory. Cancer today. Available at: https://gco.iarc.fr/today/home (accessed March 2022).
  • Eeles RA. Genetic predisposition to prostate cancer. Prostate Cancer Prostatic Dis 1999;2(1):9–15.
  • De Felice F, Tombolini V, Marampon F, Musella A, Marchetti C. Defective DNA repair mechanisms in prostate cancer: impact of olaparib. Drug Des Devel Ther 2017;11:547–552.
  • James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, et al. Survival with newly diagnosed metastatic prostate cancer in the “Docetaxel Era”: data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol 2015;67(6):1028–1038.
  • Sweeney CJ, Chen Y-H, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373(8):737–746.
  • Lang S, Swift S, White H, Misso K, Kleijnen J, Quek R. A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer. Int J Oncol 2019;55:597–616.
  • Iqbal S, Rattu MA, Shah N. Role of PARP inhibitors in BRCA-related malignancies. US Pharmacist 2018;9(43):HS10–HS16.
  • Mohler JL, Antonarakis ES. NCCN guidelines updates: management of prostate cancer. J Natl Compr Canc Netw 2019;17(5.5):583–586.
  • Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31(9):1119–1134.
  • Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 2015;373(18):1697–1708.
  • Hussain M, Mateo J, Fizazi K, Saad F, Shore ND, Sandhu S, et al. LBA12_PROfound: phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. Ann Oncol 2019;30:v881–v882.
  • Cattrini C, España R, Mennitto A, Bersanelli M, Castro E, Olmos D, et al. Optimal sequencing and predictive biomarkers in patients with advanced prostate cancer. Cancers 2021;13(18):4522.
  • Pomerantz MM, Spisák S, Jia L, Cronin AM, Csabai I, Ledet E, et al. The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer 2017;123(18):3532–3539.
  • Views: 644
    HTML downloads: 114
    PDF downloads: 479


    Published: 2022-05-24
    Issue: 2022: Vol 9 No 5 (view)


    How to cite:
    1.
    Costa I, Reis J, Meireles S, Ribeiro MJ, Augusto I, Barbosa M. Metastatic Castration-Resistant Prostate Cancer with BRCA2 Mutation: The Challenge Incorporating PARP Inhibitors and Platinum in Treatment Sequencing. EJCRIM 2022;9 doi:10.12890/2022_003331.

    Most read articles by the same author(s)